Rhodia Pharma expands in UK

Related tags Pharmacology Rhodia

Rhodia Pharma Solutions has completed a new extension to its
production operation in Dudley, outside Newcastle, in the UK to
strengthen its ability to provide custom manufacturing services to
pharmaceutical companies.

The upgrade comes at a time when Rhodia is in the throes of a major restructuring drive and lends further weight to the idea that the pharmaceuticals business is one of the group's stronger units.

Last year, RPS consolidated its US activities in its development services unit into a new 101,000 square-foot purpose built facility at DuPont Pharmaceuticals' site at Chambers, New Jersey that came on-line in early 2004.

The upgrade to the Dudley site includes a new chemical reactor stream that the company said brings more flexibility to the plant and allows the introduction of new products at minimal cost, two new pharmaceutical product isolation facilities, and improvement to gas emission technology to ensure compliance with regulations.

The Dudley facility is a large-scale general purpose cGMP active pharmaceutical ingredients and intermediates manufacturing operation. Formerly a Sterling Drug facility, it employs 350 people.

"These strategic actions allow us to increase our line of services to pharma customers,"​ said Nick Green, president of PS.

He insisted that outsourcing remains a valid business model, despite the fact that consolidation of pharmaceutical companies and the lower number of new chemical entities (NCE) compared to the late 1990s have resulted in more unused capacity.

Meanwhile, Rhodia has arranged a refinancing plan totalling about €1.8 billion, part of a restructuring of its finances that is aimed at avoiding a cash crisis next year.

The company said that under the refinancing plan it would increase capital by about €450 million, issue bonds to raise at least €600 million, and would have access to a line of bank credit totalling €758 million.

The company is in the process of selling off assets to help bring down debt that earlier this year topped €2.1 billion.

Rhodia has posted three years of losses and expects two more unprofitable years because of escalating raw materials costs, the impact of the weak US dollar on its euro-recorded sales and a slump in demand for its products and services.

The company narrowly avoided defaulting​ on its loans in December after reaching an agreement with banks on refinancing part of its debt.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more